Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy

NCT01431391 is registered in ClinicalTrials.gov with Dendreon as lead sponsor.

NCT NCT01431391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01431391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy
Lead sponsor
Dendreon
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
December 31, 2014
Enrollment
68 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostatic adenocarcinoma, prostatic neoplasm